Original language | English (US) |
---|---|
Pages (from-to) | 299-301 |
Number of pages | 3 |
Journal | JAMA - Journal of the American Medical Association |
Volume | 324 |
Issue number | 3 |
DOIs | |
State | Published - Jul 21 2020 |
ASJC Scopus subject areas
- Medicine(all)
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Use of Risk Evaluation and Mitigation Strategies by the US Food and Drug Administration, 2008-2019. / Guadamuz, Jenny S.; Qato, Dima M.; Alexander, G. Caleb.
In: JAMA - Journal of the American Medical Association, Vol. 324, No. 3, 21.07.2020, p. 299-301.Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Use of Risk Evaluation and Mitigation Strategies by the US Food and Drug Administration, 2008-2019
AU - Guadamuz, Jenny S.
AU - Qato, Dima M.
AU - Alexander, G. Caleb
N1 - Funding Information: Corresponding Author: Paula P. Schnurr, PhD, National Center for PTSD, VA Medical Center, 215 N Main St, White River Junction, VT 05005 (paula.schnurr @dartmouth.edu). Conflict of Interest Disclosures: All authors reported being coauthors of the VA/DoD PTSD Practice Guideline. Dr Schnurr reported receiving salary support from the VA; receiving grants from the VA, the DoD, and the National Institute of Mental Health and personal fees from Nobilis Therapeutics; and being a past member of the scientific advisory board for Nobilis Therapeutics. Dr Norman reported receiving grants from the VA, the DoD, and the National Institute of Mental Health and royalties from Elsevier. Dr Hamblen reported receiving research funding from the VA. Funding Information: Funding/Support: Dr Guadamuz and Dr Qato receive funding from the Robert Wood Johnson Foundation as part of the Health Policy Research Scholar program and the Clinical Scholar program, respectively. Dr Guadamuz also receives funding from the National Heart, Lung, and Blood Institute (T-32-HL-125-294-01A1).
PY - 2020/7/21
Y1 - 2020/7/21
UR - http://www.scopus.com/inward/record.url?scp=85088607923&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85088607923&partnerID=8YFLogxK
U2 - 10.1001/jama.2020.6611
DO - 10.1001/jama.2020.6611
M3 - Letter
C2 - 32692379
AN - SCOPUS:85088607923
VL - 324
SP - 299
EP - 301
JO - JAMA - Journal of the American Medical Association
JF - JAMA - Journal of the American Medical Association
SN - 0098-7484
IS - 3
ER -